케이엠알

비상장계속사업자

Korea Medical Resources.Ltd.

남기복

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

케이엠알

Business Reg. No. 1238154133 · CEO 남기복

I.Investment Overview

Target케이엠알 (1238154133)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명케이엠알
영문명Korea Medical Resources.Ltd.
대표자남기복
사업자등록번호1238154133
법인등록번호1341110071500
설립일2000.02.01

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW409.82021554.52022586.52023465.12024466.72025
영업이익100M KRW41.9202145.5202240.7202333.52024542025
순이익100M KRW36.2202137.3202227.6202327.8202443.42025
Item20252024202320222021
자산총계304.1억원335.7억원329.7억원294.9억원320.8억원
부채총계152.9억원193.3억원195.2억원141.1억원172.5억원
자본총계151.2억원142.3억원134.5억원153.8억원148.3억원
매출액466.7억원465.1억원586.5억원554.5억원409.8억원
영업이익54억원33.5억원40.7억원45.5억원41.9억원
순이익43.4억원27.8억원27.6억원37.3억원36.2억원

VI.Financial Ratios

FY2025 basis

11.56%

영업이익률

9.31%

순이익률

14.29%

ROA

28.73%

ROE

101.09%

부채비율

49.73%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

케이엠알 투심보고서 | Alpha Lenz